Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$22.05
+2.8%
$22.65
$14.47
$26.16
$2.68B0.791.14 million shs1.11 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$102.00
+3.5%
$93.80
$59.56
$126.89
$6.98B0.2954,074 shs732,007 shs
Medtronic plc stock logo
MDT
Medtronic
$82.69
+0.2%
$89.88
$75.96
$96.25
$106.05B0.796.68 million shs8.01 million shs
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
$497.47
+1.4%
$547.29
$458.82
$624.13
$20.41B1.14916,139 shs2.26 million shs
Stryker Co. stock logo
SYK
Stryker
$350.02
+0.5%
$376.39
$314.93
$406.19
$133.60B0.931.36 million shs1.77 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$80.58
+5.5%
$70.77
$55.00
$177.37
$2.71B2.141.33 million shs1.04 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
-5.67%-11.03%+2.34%-2.14%+35.08%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-1.65%+1.34%-5.84%+2.74%+64.57%
Medtronic plc stock logo
MDT
Medtronic
-3.38%-6.09%-11.68%+2.37%+0.26%
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
-4.18%-3.52%-7.71%-13.26%-8.80%
Stryker Co. stock logo
SYK
Stryker
-4.51%-5.73%-5.01%-5.19%-0.01%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+1.27%+7.62%+12.89%+10.99%-20.16%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.5281 of 5 stars
3.61.00.03.93.43.32.5
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.3304 of 5 stars
3.51.00.04.23.72.51.9
Medtronic plc stock logo
MDT
Medtronic
4.5735 of 5 stars
3.24.03.34.02.92.50.6
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/AN/AN/AN/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
4.5089 of 5 stars
3.43.01.74.23.12.51.3
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.3809 of 5 stars
3.41.00.00.02.41.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.13
Buy$32.2946.42% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$129.4326.89% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.1416.27% Upside
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
2.60
Moderate Buy$497.43-0.01% Downside
Stryker Co. stock logo
SYK
Stryker
2.79
Moderate Buy$423.0520.87% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.82
Moderate Buy$122.7052.27% Upside

Current Analyst Ratings Breakdown

Latest LNTH, TMDX, MDT, SYK, CPRX, and MDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
Medtronic plc stock logo
MDT
Medtronic
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$93.00 ➝ $90.00
3/26/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/21/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $122.00
3/21/2025
Stryker Co. stock logo
SYK
Stryker
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$442.00 ➝ $442.00
3/11/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/4/2025
Stryker Co. stock logo
SYK
Stryker
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$422.00
3/4/2025
Medtronic plc stock logo
MDT
Medtronic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00 ➝ $107.00
3/3/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.00
2/28/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/27/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$33.00 ➝ $33.00
2/27/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $127.00
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$491.73M5.45$2.06 per share10.72$3.30 per share6.68
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B4.55$8.51 per share11.98$11.91 per share8.56
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.19$6.77 per share12.21$38.69 per share2.14
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/AN/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$22.60B5.91$13.66 per share25.62$54.08 per share6.47
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M6.14$0.15 per share530.08$4.20 per share19.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$71.41M$1.3118.6910.353.3131.01%40.79%34.87%5/6/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$326.66M$4.3716.9716.16N/A28.57%44.29%23.52%5/1/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2925.1314.182.2212.83%14.07%7.70%5/21/2025 (Estimated)
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/AN/A18.90N/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$2.99B$7.7645.1123.602.9313.25%23.58%11.37%5/1/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M$1.0185.7256.35N/A8.14%18.74%4.39%4/29/2025 (Estimated)

Latest LNTH, TMDX, MDT, SYK, CPRX, and MDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64N/AN/AN/A$377.37 millionN/A
5/1/2025Q1 2025
Stryker Co. stock logo
SYK
Stryker
$2.76N/AN/AN/A$5.68 billionN/A
4/29/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29N/AN/AN/A$123.39 millionN/A
2/27/2025Q4 2024
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
1/28/2025Q4 2024
Stryker Co. stock logo
SYK
Stryker
$3.87$4.01+$0.14$1.41$6.36 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.39%+4.14%85.11%48 Years
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
$7.041.42%N/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$3.360.96%N/A43.30%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Latest LNTH, TMDX, MDT, SYK, CPRX, and MDY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Stryker Co. stock logo
SYK
Stryker
quarterly$0.840.86%3/31/20253/31/20254/30/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
5.11
4.92
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/A
1.65
1.56
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
0.59
1.95
1.32
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.42
8.20
7.33

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Medtronic plc stock logo
MDT
Medtronic
82.06%
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/A
Stryker Co. stock logo
SYK
Stryker
77.09%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.45 million106.15 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70068.48 million68.48 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
SPDR S&P MidCap 400 ETF Trust stock logo
MDY
SPDR S&P MidCap 400 ETF Trust
N/A41.02 millionN/ANot Optionable
Stryker Co. stock logo
SYK
Stryker
51,000381.69 million359.07 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.66 million31.21 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$22.05 +0.60 (+2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$22.73 +0.68 (+3.08%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$102.00 +3.49 (+3.54%)
Closing price 04:00 PM Eastern
Extended Trading
$101.97 -0.03 (-0.03%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Medtronic stock logo

Medtronic NYSE:MDT

$82.69 +0.15 (+0.18%)
Closing price 03:59 PM Eastern
Extended Trading
$83.49 +0.81 (+0.97%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

SPDR S&P MidCap 400 ETF Trust stock logo

SPDR S&P MidCap 400 ETF Trust NYSEARCA:MDY

$497.47 +6.85 (+1.40%)
Closing price 04:10 PM Eastern
Extended Trading
$497.28 -0.20 (-0.04%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPDR S&P MidCap 400 ETF is an exchange traded fund. SPDR MidCap 400 Trust focuses to correspond to the price and yield performance of the S&P MidCap 400 Index. The S&P MidCap 400 covers over 7% of the United States equities market, and is part of a series of S&P the United States indices. The index also includes companies, which should have four consecutive quarters of positive as-reported earnings, excluding discontinued operations and extraordinary items. Its investment sectors include financials, industrials, information technology, consumer discretionary, healthcare and materials. Bank of New York acts as an investment manager.

Stryker stock logo

Stryker NYSE:SYK

$350.02 +1.63 (+0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$339.86 -10.16 (-2.90%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$80.58 +4.21 (+5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$80.49 -0.09 (-0.11%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.